Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Sirna and Epigenetic Aberrations in Ovarian Cancer Publisher Pubmed



Mirzaei H1 ; Yazdi F2 ; Salehi R3 ; Mirzaei H1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  2. 2. Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran, Iran
  3. 3. Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, 14176-13151, Iran

Source: Journal of Cancer Research and Therapeutics Published:2016


Abstract

Ovarian cancer has the most noteworthy lethal rate around gynecologic malignancies, and it is also considered as the fourth most frequent cancer in the woman in world. Two most critical barriers to treatment of ovarian malignancy are absence of early diagnostic markers and advancement of drug resistance after therapy, especially in advanced stages. Various epigenetic changes have been recognized in ovarian cancer. Recent progresses in our understanding of molecular pathogenesis of ovarian malignancy have dramatically provided potential new targets for molecularly targeted therapies. In very recent years, small interfering RNA (siRNA)-mediated gene silencing has been emerging as a novel treatment modality in preclinical studies in the light of its strong gene-specific silencing. Gene suppression mediated by RNA interference (RNAi) significantly suppressed gene expression at the messenger RNA (mRNA) and protein levels. SiRNAs have therapeutic potential for ovarian cancer through various mechanisms. In this review, we not only provide an overview of siRNA designing for epigenetic silencing of genes aberrantly expressed in ovarian cancer but also we will highlight that the epigenetically silenced genes offer new targets for therapeutic approaches based on re-expression of tumor suppressor genes via demethylating and deacetylating drugs.
Related Docs
View other Related Docs
1. Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies, Current Cancer Drug Targets (2016)
2. Molecular Mechanisms of Drug Resistance in Ovarian Cancer, Journal of Cellular Physiology (2018)
3. Dna Methylation and Microrna Patterns Are in Association With the Expression of Brca1 in Ovarian Cancer, Cellular and Molecular Biology (2016)
4. Regulation of Dna Methylation Machinery by Epi-Mirnas in Human Cancer: Emerging New Targets in Cancer Therapy, Cancer Gene Therapy (2021)
5. Effects of Caloric Restriction on Delaying the Aging Process, Journal of Isfahan Medical School (2013)
6. Epi-Mirnas: Regulators of the Histone Modification Machinery in Human Cancer, Journal of Oncology (2022)
7. Emerging Biologic and Clinical Implications of Mir-182-5P in Gynecologic Cancers, Clinical and Translational Oncology (2024)
8. Dna-Methyltransferase 3B 39179 G > T Polymorphism and Risk of Sporadic Colorectal Cancer in a Subset of Iranian Population, Journal of Research in Medical Sciences (2011)
Experts (# of related papers)
View all Related Experts
Mohammadreza Sharifi (8)
Rasoul Salehi (5)
Other Related Docs
9. Mechanisms of Apoptosis-Related Non-Coding Rnas in Ovarian Cancer: A Narrative Review, Apoptosis (2025)
10. Lack of Significance of the Brca2 Promoter Methylation Status in Different Genotypes of the Mthfr A1298c Polymorphism in Ovarian Cancer Cases in Iran, Asian Pacific Journal of Cancer Prevention (2012)
11. Involvement of Aberrant Regulation of Epigenetic Mechanisms in the Pathogenesis of Parkinson's Disease and Epigenetic-Based Therapies, Journal of Cellular Physiology (2019)
12. Computer-Driven Development of an in Silico Tool for Finding Selective Histone Deacetylase 1 Inhibitors, Molecules (2020)
13. Brca1 Promoter Methylation Status in Ovarian Cancer, Laboratory Medicine (2012)
14. The Emerging Role of Circular Rnas in Cisplatin Resistance in Ovarian Cancer: From Molecular Mechanism to Future Potential, Non-coding RNA Research (2024)
15. The Role of Dietary Polyphenols in Alternating Dna Methylation in Cancer, Critical Reviews in Food Science and Nutrition (2023)
16. Vegfr3 Suppression Through Mir-1236 Inhibits Proliferation and Induces Apoptosis in Ovarian Cancer Via Erk1/2 and Akt Signaling Pathways, Journal of Cellular Biochemistry (2023)
17. Discovery of Novel Hit Compounds As Potential Hdac1 Inhibitors: The Case of Ligand- and Structure-Based Virtual Screening, Computers in Biology and Medicine (2021)
18. Mirnas: Emerging Agents for Therapeutic Effects of Polyphenols on Ovarian Cancer, Mini-Reviews in Medicinal Chemistry (2024)
19. Computational Study for Suppression of Cd25/Il-2 Interaction, Biological Chemistry (2021)
20. Nanoparticles for Targeted Delivery of Therapeutics and Small Interfering Rnas in Hepatocellular Carcinoma, World Journal of Gastroenterology (2015)
21. Study of the Role of Sirna Mediated Promoter Methylation in Dnmt3b Knockdown and Alteration of Promoter Methylation of Cdh1, Gstp1 Genes in Mda-Mb -453 Cell Line, Iranian Journal of Pharmaceutical Research (2017)
22. Locked Nucleic Acid Anti-Mir-21 Inhibits Cell Growth and Invasive Behaviors of a Colorectal Adenocarcinoma Cell Line: Lna-Anti-Mir As a Novel Approach, Cancer Gene Therapy (2016)
23. Micrornas, Long Non-Coding Rnas, and Circular Rnas and Gynecological Cancers: Focus on Metastasis, Frontiers in Oncology (2023)
24. Genetic Advancements in Breast Cancer Treatment: A Review, Discover Oncology (2025)
25. Current Status and Perspectives Regarding Lna-Anti-Mir Oligonucleotides and Microrna Mir-21 Inhibitors As a Potential Therapeutic Option in Treatment of Colorectal Cancer, Journal of Cellular Biochemistry (2017)
26. Knockdown of Sirlnt by Antisense Lna Gapmers and Evaluation of Its Inhibitory Effect on Proliferation and Apoptosis in Mcf7 Cell Line, Indian Journal of Gynecologic Oncology (2023)
27. R0rc2 Gene Silencing in Human Th17 Cells by Sirna: Design and Evaluation of Highly Efficient Sirna, Avicenna Journal of Medical Biotechnology (2013)
28. Blockage of Hotair Reduced Cell Proliferation in Human Ovarian Cancer Cells Through Upregulation of Akt2, Indian Journal of Gynecologic Oncology (2019)
29. Micrornas in Female Infertility: An Overview, Cell Biochemistry and Function (2021)
30. A Review on Expression and Regulatory Mechanisms of Mir-337-3P in Cancer, Journal of Biomolecular Structure and Dynamics (2024)
31. Lna Inhibitor in Microrna Mir-23B As a Potential Anti-Proliferative Option in Human Hepatocellular Carcinoma, Journal of Gastrointestinal Cancer (2020)
32. Exosomal Mirnas As Novel Cancer Biomarkers: Challenges and Opportunities, Journal of Cellular Physiology (2018)
33. Antibody-Drug Therapeutic Conjugates: Potential of Antibody-Sirnas in Cancer Therapy, Journal of Cellular Physiology (2019)
34. Non-Viral Delivery Systems for Breast Cancer Gene Therapy, Current Gene Therapy (2017)
35. Hollow Inorganic Nanoparticles As Efficient Carriers for Sirna Delivery: A Comprehensive Review, Current Pharmaceutical Design (2015)
36. Microrna-30C-2-3P Regulates Er Stress and Induces Apoptosis in Ovarian Cancer Cells Underlying Er Stress, EXCLI Journal (2021)
37. Degradation of Hox Transcript Antisense Rna Provoked Apoptosis and Necrosis in Human Ovarian Cancer Cells, Indian Journal of Gynecologic Oncology (2020)
38. Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary Malignancies, PLoS ONE (2016)